Extended Data Fig. 6: In Hi-MYC mouse model of cancer, Lin−eYFP+ progenitors egress the SVZ, migrate through the blood and infiltrate the tumour, where they do not express neural stem-cell markers.
From: Progenitors from the central nervous system drive neurogenesis in cancer
a, b, After tamoxifen-induced recombination in the DCX-creERT2;loxp-eYFP Hi-MYC cancer mice at week 3 after birth, the number of Lin−eYFP + neural progenitors decreases in the SVZ at week 6 after birth (a) and—in turn—Lin−eYFP + cells emerge progressively in blood (b). Data are mean + s.e.m. Student’s t-test (one-sided, no adjustment). Sample sizes are listed in Source Data. Thirteen independent experiments. c, d, Representative FACS plots of Lin−eYFP+ cells isolated from the SVZ (c) or blood (d) of 6- or 16-week-old wild-type or Hi-MYC mice. ****P < 0.0001. e, Lin−eYFP+SCA-1−PSA-NCAM− cells in the SVZ—but not in prostate tumours—express neural stem-cell markers. Real-time quantitative PCR analyses of mRNA extracts obtained from purified subpopulations of the SVZ and prostate tumour tissues of DCX-creERT2;loxp-eYFP Hi-MYC mice. The Lin−eYFP+SCA-1−PSA-NCAM− cells from the SVZ express GFAP and GLAST, which are specific markers of neural stem cells. By contrast, Lin−eYFP+SCA-1−PSA-NCAM− cells in tumours do not express the stem-cell markers. Three independent experiments. Data are mean + s.e.m.
